Valuation: Allergy Therapeutics plc

Market Cap 332M 449M 389M 364M 626M 42.84B 636M 4.27B 1.67B 21.44B 1.69B 1.65B 71.53B P/E 2026 *
-5.77x
P/E 2027 * -
Enterprise Value 377M 509M 441M 413M 709M 48.53B 721M 4.84B 1.9B 24.29B 1.91B 1.87B 81.04B EV / Sales 2026 *
6.29x
EV / Sales 2027 * -
Free-Float
11.51%
Yield 2026 *
-
Yield 2027 * -
1 day-4.55%
Current month-12.21%
1 month-21.88%
3 months-47.50%
6 months-51.83%
Current year-52.27%
1 week 5
Extreme 5
6
1 month 5
Extreme 5
7.5
Current year 5
Extreme 5
12.1
1 year 5
Extreme 5
12.1
3 years 1.2
Extreme 1.2
12.1
5 years 0.8
Extreme 0.8
40.5
10 years 0.8
Extreme 0.8
40.5
Manager TitleAgeSince
Chief Executive Officer 62 2009-08-31
Director of Finance/CFO - 2023-08-10
Corporate Officer/Principal - 2013-04-30
Director TitleAgeSince
Director/Board Member 62 2009-08-31
Chairman 75 2011-01-03
Director/Board Member 69 2017-06-05
Date Insider Type Main position Quantity % Market Cap.
6/13/26 Free

Chief Financial Officer

2,300,000 0.0363%
3/12/26
ZQ Capital Ltd.
SellCompany 1,840,000 0.0300%
3/12/26
ZQ Capital Ltd.
OthersCompany 150,925,926 2.4575%
Change 5-day change 1-year change 3-year change Capi.($)
-4.55%0.00%-37.87%+105.88% 449M
-1.37%+4.78%+45.99%-1.23% 79.58B
+2.55%+9.01%+1.40%+30.65% 52.73B
+0.49%+1.30%+21.22%+175.79% 49.77B
+0.08%+5.95%-47.62%-47.36% 46.77B
-1.56%-2.19%+59.29%-25.50% 30.13B
-0.39%+0.39%+52.89%+83.63% 24.54B
+1.27%+6.28%+137.81%-40.32% 24.18B
-0.58%+5.26%+8.88%+193.36% 21.2B
-5.89%+22.69%-0.99%+796.32% 16.14B
Average -0.99%+165.51%+24.10%+127.12% 34.55B
Weighted average by Cap. -0.23%+270.08%+26.44%+73.41%

Financials

2026 *2027 *
Net sales 59.9M 80.92M 70.13M 65.65M 113M 7.72B 115M 770M 302M 3.86B 304M 297M 12.89B -
Net income -55.7M -75.25M -65.21M -61.05M -105M -7.18B -107M -716M -280M -3.59B -283M -276M -11.98B -
Net Debt 44.2M 59.71M 51.75M 48.44M 83.18M 5.7B 84.57M 568M 223M 2.85B 224M 219M 9.51B -
Logo Allergy Therapeutics plc
Allergy Therapeutics plc is a United Kingdom-based international commercial biotechnology company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum free immunotherapies that have the potential to cure disease. It sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional 10 countries. It sells both injectable and sublingual (oral) allergen-specific immunotherapies. Its pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. Its therapies are traded under various brand names depending on the market, such as Pollinex Quattro, Polligoid and TA Graser Top. Its commercial products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics and Acarovac Plus. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL, and VLP Peanut.
Employees
584
Date Price Change Volume
26-08-11 GBX 5.250 -4.55% 625,315
26-08-10 GBX 5.500 0.00% 438,277
26-08-07 GBX 5.500 +4.76% 121,750
26-08-06 GBX 5.250 +5.00% 1,058,001
26-08-05 GBX 5.000 -4.76% 132,799
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0525GBP
Average target price
0.1300GBP
Spread / Average Target
+147.62%

Annual profits - Rate of surprise